GLG News by Revlimid Prescribers: Hematologists (US)

This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).

Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.

Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)

Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

"In summary, THEY showed that the infusion of a clonal population of CD4+ T cells with specificity for a single tumor-associated antigen caused complete regression of a tumor. During regression of the tumor, this clone appears to have induced the patient's own T cells to respond to other antigens of...

Very preliminary but this agent may offer a targeted, more "natural" approach to the MPD's- Polycythemia Vera, Myelofibrosis and Primary thrombocytosis.

Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...

Tight Glucose control in type 2 diabetes mellitus did not result in improved survival and possibly had a negative impact.

The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.

This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)